Stephen J. Gould, PhD
Stephen J. Gould, is co-director of the Johns Hopkins University School of Medicine’s Graduate Program in biological chemistry. In his research, Dr. Gould investigates the formation of HIV particles, which develop as the virus escapes from one cell and infects others. His research has led to the identification of new targets for anti-HIV therapy. In addition to his professorship, Dr. Gould serves as both the president of the American Society of Exosomes and Microvesicles and the editor-in-chief of Exosomes and Microvesicles. He also sits on the editorial board of the Journal of Extracellular Vesicles and serves as an ad hoc reviewer for publications, including the Proceedings of the National Academy of Sciences (United States), Cell, Science and Journal of Cell Biology. He has organized a number of scientific conferences, delivered scores of invited lectures, published approximately 110 journal articles, and authored and co-authored seven book chapters. Dr. Gould earned his doctoral degree in biology at the University of California, San Diego, where he completed a post-doctoral fellowship. He also holds a bachelor’s degree in aquatic biology from the University of California, Santa Barbara.
Florin Marian Selaru, MD
Dr. Selaru is currently an Assistant Professor of Medicine and Oncology, Division of Gastroenterology and Hepatology and Sidney Kimmel Cancer Center, Johns Hopkins University. He is also a member of the Institute of Nanobiotechnology at Johns Hopkins University. Since its start in 2009, Dr. Selaru has also been directing his basic and applied science laboratory in cancer research at Johns Hopkins. Dr. Selaru's focus is in bringing cutting edge molecular biology, genetics and engineering to the care of patients with gastroenterological disorders, in particular patients with GI cancers. His laboratory focuses on premalignant conditions such as colonic inflammation that can lead to colon cancer and inflammatory conditions of the hepatobiliary tract (such as primary sclerosing cholangitis or liver cirrhosis/fibrosis) that can lead to cholangiocarcinoma or hepatocellular cancer. The laboratory studies genetic alterations that can be utilized to understand disease progression from normal tissue to inflamed tissue to cancer, as well as to develop markers of early cancer. In addition, the laboratory focuses on epigenetic alterations, such as microRNA. Our recent studies demonstrated a rich, and previously unknown, intercellular communication between cancer cells and stroma, through small vesicles (exosomes) loaded with microRNA species. Last, the laboratory''s focus is to bring microdevices and information technology to medicine.
Luke Boulter, PhD
Luke Boulter leads a number of research projects looking at the fundamental biology of cholangiocarcinoma at the MRC Human Genetics Unit, located in Edinburgh, UK. The lab focuses on understanding the role of the Wnt pathways in cholangiocarcinoma growth and exploiting this as a therapeutic target; as well as using a combination of computational and molecular approaches to distinguish which genetic changes in cholangiocarcinoma are causative. His team has developed and uses a number of animal models of cholangiocarcinoma to accurately model human dieases. Dr. Boulter and his team's ultimate goal is to develop a panel of compounds that will be useful in a spectrum of patients following disease stratification.
John Bridgewater leads the clinical trials portfolio of the National Cancer Research Institute (NCRI) Hepatobiliary group (ABC-02 paper NEJM1, New EPOC paper Lancet Oncology). He founded the International Biliary Tract Cancer Collaborators group and leads the NCRI Genomics England programme for upper gastrointestinal cancers. He established the ABC series of studies which have defined the standard of care for advanced biliary tract cancer and is co-chief investigator for the BILCAP study, an adjuvant study which will define the standard of care. He is currently working on a series of multidisciplinary studies including a including a study with Hennig Walczak (UCL CI) using multiple immune phenotype measurements to guide personalised, sequential immunotherapy in a phase 1 programme in heptabiliary cancers.
Helen Morement founded AMMF – The Cholangiocarcinoma Charity in 2002. Registered with the UK Charity Commission, AMMF is the UK’s only charity dedicated to cholangiocarcinoma.ith a small team, she works to achieve AMMF’s aims of raising the awareness of cholangiocarcinoma, encouraging and supporting research, and providing information and support to patients and their families. AMMF works throughout the UK and collaborates internationally, actively working towards developing relationships with other organizations dedicated to this disease in the US and in Thailand, the latter of which has the world’s highest incidence of cholangiocarcinoma. Helen is an active member of the NCRI (National Cancer Research Institute) Upper Gastrointestinal Hepatobiliary Clinical Trials group, the Biliary Tract Cancers Trial Management group and the International Biliary Tract Cancer Collaborators group, representing the experience and views of patients within each group. She reviews patient clinical trials information, and information provided by larger, more generalized cancer charities. She is also a board director of Cancer52, the UK alliance of 90+ rare cancer charities, working to address inequality and improve outcomes for rare cancer patients.
Lewis R. Roberts, MB, ChB, PhD
Dr. Lewis R. Roberts' laboratory seeks to understand the mechanisms by which liver and biliary cancers develop, grow and spread, and is particularly interested in identifying the critical pathways needed for the growth of individual cancers. The laboratory's second goal is to develop and validate methods for early detection, diagnosis and treatment of primary liver, biliary and pancreas cancers. In support of these goals, Dr. Roberts also coordinates the International Hepatobiliary Neoplasia Registry and Biorepository (IHNB). IHNB is a collaborative effort by many medical centers to collect clinical and risk factor information as well as blood and tissue samples to support research on liver and biliary cancers. As a clinician, Dr. Roberts' expertise is in the diagnosis and multidisciplinary management of benign and malignant liver masses, including hepatic adenomas, hepatocellular carcinomas, bile duct cancers (cholangiocarcinomas) and gallbladder cancers.